Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational Study

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  White, Patrick ^a   Thornton, Hannah ^a   Pinnock, Hilary ^b   Georgopoulou, Sofia ^a   Booth, Helen P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; PREDNISOLONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DRUG COST; DRUG DELIVERY DEVICE; DRUG SAFETY; ETHNICITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CODING; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA; UNNECESSARY PROCEDURE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; CROSS-SECTIONAL STUDIES; HUMANS; LONDON; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; UNNECESSARY PROCEDURES;

EID: 84885961764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075221     Document Type: Article

References (34)

1. Miravitlles M, de la Roza C, Naberan K, Lamban M, Gobartt E, et al. (2007) Use of spirometry and patterns of prescribing in COPD in primary care. Respir_Med 101: 1753-1760. PubMed: 17448651.
2. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS, (2008) Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res 9: 62. doi:10.1186/1465-9921-9-62. PubMed: 18710575.
3. Jebrak G, Initiatives B, (2010) COPD routine management in France: are guidelines used in clinical practice?. Rev Mal Respir 27: 11-18. doi:10.1016/S0761-8425(10)70003-6. PubMed: 20146947.
4. Strong M, South G, Carlisle R, (2009) The UK Quality and Outcomes Framework pay-for-performance scheme and spirometry: rewarding quality or just quantity? A cross-sectional study in Rotherham, UK. BMC Health Serv_Res 9: 108. doi:10.1186/1472-6963-9-108. PubMed: 19558719.
5. White P, Wong W, Fleming T, Gray B, (2007) Primary care spirometry: test quality and the feasibility and usefulness of specialist reporting. Br_J_Gen_Pract 57: 701-705. PubMed: 17761057.
6. Rabe KF, (2007) Treating COPD--the TORCH trial, P values, and the Dodo. N Engl J Med 356: 851-854. doi:10.1056/NEJMe068307. PubMed: 17314345.
7. de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martín-Centeno A, Gobartt-Vázquez E, et al. (2011) Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 189: 199-206. doi:10.1007/s00408-011-9289-0. PubMed: 21499887.
8. Sin DD, Man SF, (2010) Steroids in COPD: still up in the air? Eur_Respir_J 35: 949-951. PubMed: 20436169.
9. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, et al. (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur_Respir_J 21: 74-81. PubMed: 12570112.
10. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, et al. (2008) Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir_Med 102: 1099-1108. PubMed: 18614347.
11. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, et al. (2008) Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 68: 1975-2000. doi:10.2165/00003495-200868140-00004. PubMed: 18778120.
12. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, et al. (2009) Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69: 549-565. doi:10.2165/00003495-200969050-00004. PubMed: 19368417.
13. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEnglJMed 356: 775-789. doi:10.1056/NEJMoa063070.
14. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, et al. (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. AmJRespirCrit Care Med 177: 19-26.
15. Kardos P, Wencker M, Glaab T, Vogelmeier C, (2007) Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. AmJRespirCrit Care Med 175: 144-149. PubMed: 17053207.
16. Jones PW, Quirk FH, Baveystock CM, (1991) The St George's Respiratory Questionnaire. Respir Med 85 (Suppl B):: 25-31. doi:10.1016/S0954-6111(06)80166-6. PubMed: 1759018.
17. Rabe KF, Wedzicha JA, (2011) Controversies in treatment of chronic obstructive pulmonary disease. Lancet 378: 1038-1047. doi:10.1016/S0140-6736(11)61295-6. PubMed: 21907867.
18. National Clinical Guideline Centre (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London. 1-673 p.
19. Global Initiative for Chronic Obstructive Lung Disease (2011) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011). Global Initiative for Chronic Obstructive Lung Disease, Inc.
20. Loke YK, Cavallazzi R, Singh S, (2011) Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66: 699-708. doi:10.1136/thx.2011.160028. PubMed: 21602540.
21. Singh S, Loke YK, (2010) An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. IntJchronObstructPulmonDis 5: 189-195.
22. Singh S, Loke YK, (2010) Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr_Opin_Pulm_Med 16: 118-122. PubMed: 19926996.
23. Noble M, McLennon D, Wilkinson K, Whitworth A, Barnes H, et al. (2008) The English Indices of Deprivation 2007. London, UK: Department for Communities and Local Government.
24. the NHS Information Centre (2011) Prescribing and Primary Care Services. Quality Outcomes Framework Achiev Data 2010/11. Leeds: The Health and Social Care Information Centre.
25. Williams RL, (2000) A note on robust variance estimation for cluster-correlated data. Biometrics 56: 645-646. doi:10.1111/j.0006-341X.2000.00645.x. PubMed: 10877330.
26. Global Initiative for Chronic Obstructive Lung Disease (2009). Global Strategy Diagn Manage Prev Chronic Obstructive Pulm Dis (updated 2009).
27. Singh S, Amin AV, Loke YK, (2009) Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. ArchInternMed 169: 219-229. PubMed: 19204211.
28. British, Medical Association, Royal Pharmaceutical Society (2011) British National Formulary. London: BMJ Publishing Group Group and Pharmaceutical Press. 1036 pp.
29. Britton M, (2003) The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir_Med 97 (Suppl C):: S71-S79. PubMed: 12647945.
30. Neighbourhood Statistics and Census Output (2011) QS201EW; Office for National Statistics, editor Titchfield. Retrieved onpublished at whilst December year 1111 from http://neighbourhood.statistics.gov.uk/dissemination/LeadMetadataDownloadPDF.do?downloadId=32865. Accessed 16 08 2013.
31. Trappenburg JC, van Deventer AC, Troosters T, Verheij TJ, Schrijvers AJ, et al. (2011) The impact of using different symptom-based exacerbation algorithms in patients with COPD. Eur_Respir_J 37: 1260-1268. PubMed: 21177839.
32. Lucas A, Smeenk F, Smeele I, Brouwer T, van SO, (2007) The validity of diagnostic support of an asthma/COPD service in primary care. Br_J_Gen_Pract 57: 892-896. PubMed: 17976290.
33. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, et al. (2008) Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 15: 13-19. PubMed: 18292848.
34. British Thoracic Society, Scottish Intercollegiate Guidelines Network, (2011) British Guideline on the Management of Asthma: A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network and British Thoracic Society. pp. pp. 1-147.